Marc J. Braunstein, MD, PhD

Articles

Dr. Braunstein on the Role of Daratumumab in Multiple Myeloma

January 12th 2021

Marc J. Braunstein, MD, PhD, discusses the role of daratumumab in multiple myeloma.

Dr. Braunstein on Management Strategies in Multiple Myeloma

January 7th 2021

Marc J. Braunstein, MD, PhD, discusses management strategies in multiple myeloma.

Dr. Braunstein on the Expanding Armamentarium in Multiple Myeloma

December 18th 2020

Marc J. Braunstein, MD, PhD, discusses the expanding treatment armamentarium in multiple myeloma.

Should All Elderly Patients With Newly Diagnosed Multiple Myeloma Receive Monoclonal Antibodies?

November 17th 2020

In light of the recent approvals of combination anti-myeloma regimens containing monoclonal antibodies, as well as the robust pipeline of novel targeted agents likely to be approved in the next year, there is much optimism in the field of multiple myeloma.

Dr. Braunstein on the Utility of Maintenance Therapy in Multiple Myeloma

July 7th 2020

Marc J. Braunstein, MD, PhD, discusses the utility of maintenance therapy in patients with multiple myeloma.

Dr. Braunstein on Updated Results of the GRIFFIN Trial in Multiple Myeloma

May 13th 2020

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

Dr. Braunstein on Updated Results of the GRIFFIN Trial in Multiple Myeloma

May 12th 2020

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

Dr. Braunstein on Quadruplet Therapies in Multiple Myeloma

May 9th 2020

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Dr. Braunstein on Considerations for Stem Cell Transplant Eligibility in Myeloma

April 16th 2020

Marc J. Braunstein, MD, PhD, factors to consider when determining whether a patient with multiple myeloma is eligible for stem cell transplant.

Dr. Braunstein on Transplant Eligibility in Multiple Myeloma

April 3rd 2020

Marc J. Braunstein, MD, PhD, discusses transplant eligibility in multiple myeloma.

Dr. Braunstein on the Bone Marrow Microenvironment in Multiple Myeloma

November 27th 2019

Marc J. Braunstein, MD, PhD, discusses challenges pertaining to the bone marrow microenvironment in multiple myeloma.

Dr. Braunstein on Reclassifying Ultra High-Risk Smoldering Multiple Myeloma

November 20th 2019

Marc J. Braunstein, MD, PhD, discusses the ultra–high-risk patient population in smoldering multiple myeloma.